Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Identifieur interne : 003A81 ( Ncbi/Merge ); précédent : 003A80; suivant : 003A82Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Auteurs : Joep Van Der Leeuw [Pays-Bas] ; Frank L J. Visseren [Pays-Bas] ; Mark Woodward [Australie] ; Yolanda Van Der Graaf [Pays-Bas] ; Diederick E. Grobbee [Pays-Bas] ; Stephen Harrap [Australie] ; Simon Heller [Royaume-Uni] ; Giuseppe Mancia [Italie] ; Michel Marre [France] ; Neil Poulter [Royaume-Uni] ; Sophia Zoungas [Australie] ; John Chalmers [Australie]Source :
- Diabetologia [ 1432-0428 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antihypertenseurs (effets indésirables), Antihypertenseurs (usage thérapeutique), Association médicamenteuse, Comportement de réduction des risques, Diabète de type 2 (traitement médicamenteux), Facteurs de risque, Femelle, Gliclazide (effets indésirables), Gliclazide (usage thérapeutique), Humains, Hypoglycémiants (effets indésirables), Hypoglycémiants (usage thérapeutique), Hypoglycémie (traitement médicamenteux), Hémoglobine A glycosylée (métabolisme), Indapamide (effets indésirables), Indapamide (usage thérapeutique), Maladies cardiovasculaires (), Mâle, Médecine individualisée (), Périndopril (effets indésirables), Périndopril (usage thérapeutique), Sujet âgé.
- MESH :
- effets indésirables : Antihypertenseurs, Gliclazide, Hypoglycémiants, Indapamide, Périndopril.
- métabolisme : Hémoglobine A glycosylée.
- traitement médicamenteux : Diabète de type 2, Hypoglycémie.
- usage thérapeutique : Antihypertenseurs, Gliclazide, Hypoglycémiants, Indapamide, Périndopril.
- Adulte d'âge moyen, Association médicamenteuse, Comportement de réduction des risques, Facteurs de risque, Femelle, Humains, Maladies cardiovasculaires, Mâle, Médecine individualisée, Sujet âgé.
English descriptors
- KwdEn :
- Aged, Antihypertensive Agents (adverse effects), Antihypertensive Agents (therapeutic use), Cardiovascular Diseases (prevention & control), Diabetes Mellitus, Type 2 (drug therapy), Drug Combinations, Female, Gliclazide (adverse effects), Gliclazide (therapeutic use), Hemoglobin A, Glycosylated (metabolism), Humans, Hypoglycemia (drug therapy), Hypoglycemic Agents (adverse effects), Hypoglycemic Agents (therapeutic use), Indapamide (adverse effects), Indapamide (therapeutic use), Male, Middle Aged, Perindopril (adverse effects), Perindopril (therapeutic use), Precision Medicine (methods), Risk Factors, Risk Reduction Behavior.
- MESH :
- chemical , adverse effects : Antihypertensive Agents, Gliclazide, Hypoglycemic Agents, Indapamide, Perindopril.
- chemical , metabolism : Hemoglobin A, Glycosylated.
- chemical , therapeutic use : Antihypertensive Agents, Gliclazide, Hypoglycemic Agents, Indapamide, Perindopril.
- drug therapy : Diabetes Mellitus, Type 2, Hypoglycemia.
- methods : Precision Medicine.
- prevention & control : Cardiovascular Diseases.
- Aged, Drug Combinations, Female, Humans, Male, Middle Aged, Risk Factors, Risk Reduction Behavior.
Abstract
Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes.
DOI: 10.1007/s00125-016-4082-5
PubMed: 27586250
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001455
- to stream PubMed, to step Curation: 001433
- to stream PubMed, to step Checkpoint: 001433
Links to Exploration step
pubmed:27586250Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.</title><author><name sortKey="Van Der Leeuw, Joep" sort="Van Der Leeuw, Joep" uniqKey="Van Der Leeuw J" first="Joep" last="Van Der Leeuw">Joep Van Der Leeuw</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Visseren, Frank L J" sort="Visseren, Frank L J" uniqKey="Visseren F" first="Frank L J" last="Visseren">Frank L J. Visseren</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands. f.l.j.visseren@umcutrecht.nl.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Van Der Graaf, Yolanda" sort="Van Der Graaf, Yolanda" uniqKey="Van Der Graaf Y" first="Yolanda" last="Van Der Graaf">Yolanda Van Der Graaf</name><affiliation wicri:level="3"><nlm:affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E" last="Grobbee">Diederick E. Grobbee</name><affiliation wicri:level="3"><nlm:affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name><affiliation wicri:level="4"><nlm:affiliation>The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Heller, Simon" sort="Heller, Simon" uniqKey="Heller S" first="Simon" last="Heller">Simon Heller</name><affiliation wicri:level="1"><nlm:affiliation>University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Mancia, Giuseppe" sort="Mancia, Giuseppe" uniqKey="Mancia G" first="Giuseppe" last="Mancia">Giuseppe Mancia</name><affiliation wicri:level="3"><nlm:affiliation>Istituto Auxologico Italiano, University of Milano-Bicocca, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Auxologico Italiano, University of Milano-Bicocca, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name><affiliation wicri:level="3"><nlm:affiliation>International Centre for Circulatory Health, Imperial College, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>International Centre for Circulatory Health, Imperial College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27586250</idno><idno type="pmid">27586250</idno><idno type="doi">10.1007/s00125-016-4082-5</idno><idno type="wicri:Area/PubMed/Corpus">001455</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001455</idno><idno type="wicri:Area/PubMed/Curation">001433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001433</idno><idno type="wicri:Area/PubMed/Checkpoint">001433</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001433</idno><idno type="wicri:Area/Ncbi/Merge">003A81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.</title><author><name sortKey="Van Der Leeuw, Joep" sort="Van Der Leeuw, Joep" uniqKey="Van Der Leeuw J" first="Joep" last="Van Der Leeuw">Joep Van Der Leeuw</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Visseren, Frank L J" sort="Visseren, Frank L J" uniqKey="Visseren F" first="Frank L J" last="Visseren">Frank L J. Visseren</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands. f.l.j.visseren@umcutrecht.nl.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Van Der Graaf, Yolanda" sort="Van Der Graaf, Yolanda" uniqKey="Van Der Graaf Y" first="Yolanda" last="Van Der Graaf">Yolanda Van Der Graaf</name><affiliation wicri:level="3"><nlm:affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E" last="Grobbee">Diederick E. Grobbee</name><affiliation wicri:level="3"><nlm:affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht</wicri:regionArea><placeName><settlement type="city">Utrecht</settlement><region nuts="2" type="province">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name><affiliation wicri:level="4"><nlm:affiliation>The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Heller, Simon" sort="Heller, Simon" uniqKey="Heller S" first="Simon" last="Heller">Simon Heller</name><affiliation wicri:level="1"><nlm:affiliation>University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield</wicri:regionArea><wicri:noRegion>Sheffield</wicri:noRegion></affiliation></author><author><name sortKey="Mancia, Giuseppe" sort="Mancia, Giuseppe" uniqKey="Mancia G" first="Giuseppe" last="Mancia">Giuseppe Mancia</name><affiliation wicri:level="3"><nlm:affiliation>Istituto Auxologico Italiano, University of Milano-Bicocca, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Auxologico Italiano, University of Milano-Bicocca, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name><affiliation wicri:level="3"><nlm:affiliation>International Centre for Circulatory Health, Imperial College, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>International Centre for Circulatory Health, Imperial College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The George Institute for Global Health, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author></analytic><series><title level="j">Diabetologia</title><idno type="eISSN">1432-0428</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antihypertensive Agents (adverse effects)</term><term>Antihypertensive Agents (therapeutic use)</term><term>Cardiovascular Diseases (prevention & control)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Drug Combinations</term><term>Female</term><term>Gliclazide (adverse effects)</term><term>Gliclazide (therapeutic use)</term><term>Hemoglobin A, Glycosylated (metabolism)</term><term>Humans</term><term>Hypoglycemia (drug therapy)</term><term>Hypoglycemic Agents (adverse effects)</term><term>Hypoglycemic Agents (therapeutic use)</term><term>Indapamide (adverse effects)</term><term>Indapamide (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Perindopril (adverse effects)</term><term>Perindopril (therapeutic use)</term><term>Precision Medicine (methods)</term><term>Risk Factors</term><term>Risk Reduction Behavior</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antihypertenseurs (effets indésirables)</term><term>Antihypertenseurs (usage thérapeutique)</term><term>Association médicamenteuse</term><term>Comportement de réduction des risques</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Facteurs de risque</term><term>Femelle</term><term>Gliclazide (effets indésirables)</term><term>Gliclazide (usage thérapeutique)</term><term>Humains</term><term>Hypoglycémiants (effets indésirables)</term><term>Hypoglycémiants (usage thérapeutique)</term><term>Hypoglycémie (traitement médicamenteux)</term><term>Hémoglobine A glycosylée (métabolisme)</term><term>Indapamide (effets indésirables)</term><term>Indapamide (usage thérapeutique)</term><term>Maladies cardiovasculaires ()</term><term>Mâle</term><term>Médecine individualisée ()</term><term>Périndopril (effets indésirables)</term><term>Périndopril (usage thérapeutique)</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antihypertensive Agents</term><term>Gliclazide</term><term>Hypoglycemic Agents</term><term>Indapamide</term><term>Perindopril</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Hemoglobin A, Glycosylated</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antihypertensive Agents</term><term>Gliclazide</term><term>Hypoglycemic Agents</term><term>Indapamide</term><term>Perindopril</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term><term>Hypoglycemia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antihypertenseurs</term><term>Gliclazide</term><term>Hypoglycémiants</term><term>Indapamide</term><term>Périndopril</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Precision Medicine</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hémoglobine A glycosylée</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term><term>Hypoglycémie</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antihypertenseurs</term><term>Gliclazide</term><term>Hypoglycémiants</term><term>Indapamide</term><term>Périndopril</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Risk Reduction Behavior</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Association médicamenteuse</term><term>Comportement de réduction des risques</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Maladies cardiovasculaires</term><term>Mâle</term><term>Médecine individualisée</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27586250</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>02</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.</ArticleTitle><Pagination><MedlinePgn>2603-2612</MedlinePgn></Pagination><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">Intensive glucose control reduces the risk of vascular complications while increasing the risk of severe hypoglycaemia at a group level. We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a post hoc analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, a randomised controlled trial evaluating standard vs intensive glucose control (HbA1c target ≤6.5% [48 mmol/mol]). In 11,140 participants, we estimated the individual 5 year absolute risk reduction (ARR) for the composite outcome of major micro- and macrovascular events and absolute risk increase (ARI) for severe hypoglycaemia for intensive vs standard glucose control. Predictions were based on competing risks models including clinical characteristics and randomised treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Based on these models, 76% of patients had a substantial estimated 5 year ARR for major vascular events (>1%, 5 year number-needed-to-benefit [NNTB5] <100) and 1% had a small ARR (<0.5%, NNTB5 >200). Similarly, 36% of patients had a substantial estimated ARI for severe hypoglycaemia (5 year number-needed-to-harm [NNTH5] <100) and 29% had a small ARI (NNTH5 >200). When assigning similar or half the weight to severe hypoglycaemia compared with a major vascular event, net benefit was positive in 85% or 99% of patients, respectively. Limiting intensive treatment to the 85% patient subgroup had no significant effect on the overall incidence of major vascular events and severe hypoglycaemia compared with treating all patients.</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">Taking account of the effects of intensive glucose control on major micro- and macrovascular events and severe hypoglycaemia for individual patients, the estimated net benefit was positive in the majority of the participants in the ADVANCE trial. The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00145925.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Leeuw</LastName><ForeName>Joep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visseren</LastName><ForeName>Frank L J</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands. f.l.j.visseren@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Graaf</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grobbee</LastName><ForeName>Diederick E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrap</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heller</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancia</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istituto Auxologico Italiano, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marre</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulter</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>International Centre for Circulatory Health, Imperial College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoungas</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalmers</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00145925</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Hemoglobin A, Glycosylated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494243">indapamide, perindopril drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>F089I0511L</RegistryNumber><NameOfSubstance UI="D007190">Indapamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>G4PX8C4HKV</RegistryNumber><NameOfSubstance UI="D005907">Gliclazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y5GMK36KGY</RegistryNumber><NameOfSubstance UI="D020913">Perindopril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Diabetes Res Clin Pract. 2010 Aug;89(2):126-33</RefSource><PMID Version="1">20541825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2004 Sep 21;141(6):421-31</RefSource><PMID Version="1">15381515</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2014 Apr;35(13):837-43</RefSource><PMID Version="1">24513790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2010 Apr;33(4):721-7</RefSource><PMID Version="1">20103550</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Intern Med. 2013 Mar 11;173(5):345-51</RefSource><PMID Version="1">23400234</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ Open. 2016 Jan 13;6(1):e010210</RefSource><PMID Version="1">26769791</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2013 Oct;34(39):3035-87</RefSource><PMID Version="1">23996285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 1996 Feb 28;15(4):361-87</RefSource><PMID Version="1">8668867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2013 Jan 29;346:f324</RefSource><PMID Version="1">23360717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Sep 12;352(9131):837-53</RefSource><PMID Version="1">9742976</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2005 May;28(5):1245-9</RefSource><PMID Version="1">15855602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 1999 Dec 4;319(7223):1492-5</RefSource><PMID Version="1">10582940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2009 May 5;150(9):604-12</RefSource><PMID Version="1">19414839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jun 12;358(24):2545-59</RefSource><PMID Version="1">18539917</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jun 12;375(9731):2073-81</RefSource><PMID Version="1">20483451</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Sep 8;370(9590):829-40</RefSource><PMID Version="1">17765963</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2009 Nov;52(11):2288-98</RefSource><PMID Version="1">19655124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2011 Dec;34(12):2491-5</RefSource><PMID Version="1">21972410</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2010 Jan 08;340:b5444</RefSource><PMID Version="1">20061360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Res Clin Pract. 2014 Feb;103(2):137-49</RefSource><PMID Version="1">24630390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trials. 2010 Aug 12;11:85</RefSource><PMID Version="1">20704705</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jun 12;358(24):2560-72</RefSource><PMID Version="1">18539916</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2015 Jul 14;314(2):170-80</RefSource><PMID Version="1">26172896</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2000 Aug 12;321(7258):405-12</RefSource><PMID Version="1">10938048</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Med Res Methodol. 2006 Apr 13;6:18</RefSource><PMID Version="1">16613605</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 2006 Oct;59(10):1087-91</RefSource><PMID Version="1">16980149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Oct 9;359(15):1577-89</RefSource><PMID Version="1">18784090</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2012 Mar;55(3):636-43</RefSource><PMID Version="1">22186981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Intern Med. 2014 Aug;174(8):1227-34</RefSource><PMID Version="1">24979148</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 May 23;373(9677):1765-72</RefSource><PMID Version="1">19465231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2015 Mar;58(3):429-42</RefSource><PMID Version="1">25583541</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2009 Sep 15;151(6):394-403</RefSource><PMID Version="1">19620144</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Oct 7;363(15):1410-8</RefSource><PMID Version="1">20925543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hypertens Suppl. 2001 Nov;19(4):S21-8</RefSource><PMID Version="1">11848259</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2011 Jul 26;343:d4169</RefSource><PMID Version="1">21791495</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2013 Jun 15;32(13):2173-84</RefSource><PMID Version="1">23172755</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005907" MajorTopicYN="N">Gliclazide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007190" MajorTopicYN="N">Indapamide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020913" MajorTopicYN="N">Perindopril</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040242" MajorTopicYN="N">Risk Reduction Behavior</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glycaemic target</Keyword><Keyword MajorTopicYN="N">Hypoglycaemia</Keyword><Keyword MajorTopicYN="N">Net benefit</Keyword><Keyword MajorTopicYN="N">Personalised medicine</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">Vascular complications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27586250</ArticleId><ArticleId IdType="doi">10.1007/s00125-016-4082-5</ArticleId><ArticleId IdType="pii">10.1007/s00125-016-4082-5</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Lombardie</li><li>Nouvelle-Galles du Sud</li><li>Utrecht (province)</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Melbourne</li><li>Milan</li><li>Paris</li><li>Sydney</li><li>Utrecht</li></settlement><orgName><li>Université de Melbourne</li><li>Université de Sydney</li></orgName></list><tree><country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Van Der Leeuw, Joep" sort="Van Der Leeuw, Joep" uniqKey="Van Der Leeuw J" first="Joep" last="Van Der Leeuw">Joep Van Der Leeuw</name></region><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E" last="Grobbee">Diederick E. Grobbee</name><name sortKey="Van Der Graaf, Yolanda" sort="Van Der Graaf, Yolanda" uniqKey="Van Der Graaf Y" first="Yolanda" last="Van Der Graaf">Yolanda Van Der Graaf</name><name sortKey="Visseren, Frank L J" sort="Visseren, Frank L J" uniqKey="Visseren F" first="Frank L J" last="Visseren">Frank L J. Visseren</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name></region><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><name sortKey="Harrap, Stephen" sort="Harrap, Stephen" uniqKey="Harrap S" first="Stephen" last="Harrap">Stephen Harrap</name><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Heller, Simon" sort="Heller, Simon" uniqKey="Heller S" first="Simon" last="Heller">Simon Heller</name></noRegion><name sortKey="Poulter, Neil" sort="Poulter, Neil" uniqKey="Poulter N" first="Neil" last="Poulter">Neil Poulter</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Mancia, Giuseppe" sort="Mancia, Giuseppe" uniqKey="Mancia G" first="Giuseppe" last="Mancia">Giuseppe Mancia</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003A81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27586250
|texte= Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27586250" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |